SPIA
ACHN

Steward Partners Investment Advisory’s Achillion Pharmaceuticals ACHN Stock Holding History

Steward Partners Investment Advisory’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-915
Closed -$4K – 1809
2017
Q2 		$4K Buy
+915
New +$3.68K ﹤0.01% 1308

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Steward Partners Investment Advisory's ACHN Position: Q3 2017 in Review

Steward Partners Investment Advisory sold out of Achillion Pharmaceuticals (ACHN) in Q3 2017, closing a stake of 915 shares — an estimated $4K sold.

Steward Partners Investment Advisory first reported a position in ACHN in Q2 2017 and held it in 1 quarter. The position peaked at $4K in Q2 2017. 125 funds tracked by Wall St. Rank hold ACHN as of Q3 2017.

  • Steward Partners Investment Advisory reported no remaining Achillion Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Steward Partners Investment Advisory sold 915 Achillion Pharmaceuticals shares in Q3 2017, an estimated $4K.
  • Steward Partners Investment Advisory first reported a position in Achillion Pharmaceuticals in Q2 2017 and held it in 1 quarter.
  • Steward Partners Investment Advisory's Achillion Pharmaceuticals position peaked at $4K in Q2 2017.
  • 125 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q3 2017.

Based on Steward Partners Investment Advisory's 13F filing for Q3 2017, filed 22 Nov 2017.